Standing Order
Vertex Pharmaceuticals Incorporated

Dashboard

Vertex Pharmaceuticals Incorporated

VRTXNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$131B
Price$515.0252w $366.54 – $558.88
Conviction5/ 5
Revenue (TTM)$13.0B
Revenue growth YoY+10.5%
P/E (trailing)32.8
Gross margin85.5%
Operating margin33.2%
Net margin30.7%
52w price change+15.6%
Next earnings—

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Nov 19
    Trial initiationClinicalTrials.gov

    Phase 3b trial NCT07890909 of Povetacicept autoinjector vs Sibeprenlimab syringe begins recruiting.

  • Nov 18
    Ownership changeSEC

    Form 4 insider transaction filing dated 2026-11-18.

  • Nov 18
    Trial initiationClinicalTrials.gov

    Vertex initiates Phase 2/3 trial of povetacicept in primary membranous nephropathy (NCT07204275, recruiting).

  • Nov 18
    Ownership changeSEC

    Form 4 insider transaction filing for Vertex Pharmaceuticals.

  • Nov 17
    Trial readoutClinicalTrials.gov

    Vertex completes Phase 4 single-arm trial NCT06887959 of Suzetrigine for acute post-surgical pain.

  • Nov 17
    Trial initiationClinicalTrials.gov

    Vertex Phase 3b trial NCT07890909 of Povetacicept autoinjector vs Sibeprenlimab syringe now recruiting

  • Nov 17
    Trial readoutClinicalTrials.gov

    Vertex updates NCT06696443 Phase 3 long-term safety/efficacy trial of suzetrigine in painful DPN; status ACTIVE_NOT_RECRUITING as of 2026-11-17.

  • Nov 16
    Trial readoutClinicalTrials.gov

    Completed Phase 4 single-arm study NCT06887972 of suzetrigine for acute post-surgical pain

  • Nov 16
    Ownership changeSEC

    Form 4 insider transaction filing for Vertex Pharmaceuticals.

  • Nov 12
    Trial readoutClinicalTrials.gov

    Vertex completes Phase 4 trial NCT07538570 evaluating pain treatment after total knee arthroplasty.

  • Nov 12
    Trial readoutClinicalTrials.gov

    Vertex updates ClinicalTrials.gov NCT06747572 (PKD1 gene variants in ADPKD); status ACTIVE_NOT_RECRUITING, phase N/A, sponsor Vertex.

  • Nov 10
    Ownership changeSEC

    SEC Form 4 insider transaction filing for Vertex Pharmaceuticals.

  • Nov 2
    Financial resultsSEC

    Vertex Pharmaceuticals 8-K (items 2.02, 9.01) reports results of operations.

  • Oct 30
    OtherClinicalTrials.gov

    Phase 3 trial NCT06696443 for long-term safety/effectiveness of suzetrigine in painful diabetic peripheral neuropathy updated to active, not recruiting.

  • Oct 30
    Trial initiationClinicalTrials.gov

    Vertex initiates phase 2/3 trial (NCT07204275) of povetacicept in primary membranous nephropathy; recruiting status as of 2026-10-30.

  • Oct 30
    Trial initiationClinicalTrials.gov

    Vertex updates Phase 1 trial NCT07868926 (VX-407 ADME study) to recruiting status.

  • Oct 29
    Trial initiationClinicalTrials.gov

    Phase 2 trial (NCT07501702) of povetacicept in generalized myasthenia gravis updated to active, not recruiting.

  • Oct 28
    OtherClinicalTrials.gov

    Vertex updates ClinicalTrials.gov NCT07538570 phase 4 pain treatment post-knee arthroplasty trial status to ACTIVE_NOT_RECRUITING.

  • Oct 27
    OtherClinicalTrials.gov

    Phase 3 trial NCT05331183 for ELX/TEZ/IVA long-term safety/efficacy in non-F508del subjects updated to ACTIVE_NOT_RECRUITING.

  • Oct 27
    Trial initiationClinicalTrials.gov

    Phase 1 relative bioavailability study (NCT07813039) of VX-581 tablet formulation status updated to active, not recruiting.

Not financial advice — research and opinion only. Disclosures